Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-282723

PROSPECTUS SUPPLEMENT

(To Prospectus dated November 4, 2024)

<div align='center'>EUDA HEALTH HOLDINGS LIMITED

Convertible Warrant

Up to 2,000,000 Ordinary Shares issuable upon exercise of the Warrant</div>

We are offering, in a registered direct offering to Streeterville Capital, LLC, a Utah limited liability company and an accredited investor (the “Investor”), a convertible warrant (the “Warrant”) for an aggregate purchase price of $100,000 (before fees and expenses). Upon issuance, the Warrant will be immediately exercisable into 2,000,000 newly-issued ordinary shares, no par value each, of the Company (the “Warrant Shares”) at an exercise price of $6.00 per share for ninety (90) days (unless extended by mutual agreement) from the issuance date (the “Cash Exercise Period”). During the Cash Exercise Period, the Warrant can only be exercised for cash and the Company will have the right to require the Investor to exercise the Warrant up to 10% of the cumulative dollar trading volume during the Measurement Period (the “Forced Exercise”) if (i) the closing price of the Company’s ordinary shares on Nasdaq is at or above $7.50 for five (5) consecutive trading days (the “Measurement Period”); and (ii) the cumulative trading dollar volume over the Measurement Period (the “Cumulative Volume”) is at least $1,500,000. For a period of two (2) weeks following the end of the Cash Exercise Period (the “Repurchase Period”), the Company will have the right to repurchase any remaining portion of the outstanding Warrant in cash for $0.0625 per Warrant Share under the Warrant. At the end of the Repurchase Period (the “Expiration Date”) and provided that there are remaining outstanding Warrant Shares exercisable under the Warrant, the Investor will automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to the Investor one (1) ordinary share for every ten (10) outstanding Warrant Shares exercised under the Warrant. In the event of a breach of any term or condition of the Warrant or of any covenant of the Securities Purchase Agreement between the Company and the Investor, dated November 26, 2025 (the